Monday, March 19, 2018 @ 12:00 am
Clinerion’s Board of Directors announces the appointment of Ian Rentsch as new CEO of the company, effective April 1, 2018.
Basel, Switzerland, March 19, 2018. Clinerion, the leading supplier of patient data analytics services for clinical trial patient search and identification, and data generation for real-world evidence and market access, with access to currently more than 180 million patients’ data around the world, has appointed Ian Rentsch as its new CEO.
Rentsch brings more than 22 years of international experience in multinational pharmaceutical companies as well as in small/niche and global CROs. He joined the former Quintiles – now IQVIA – in 2012, as Head of Latin America Sales, and relocated to Europe to lead the Emerging Biopharma Segment in EMEA as Regional Head. Most recently, he took on the role of Global Demand and Business Operations Head of an E2E Strategic Alliance.
Rentsch has a German-Argentinian background and is a lawyer (UBA) and Industriekaufmann (IHK) by training.
Taking on leadership of Clinerion, Ian aims to solve the main industry challenge by bridging the divide between patients, sites, and drug developers. “Patients often lack access to clinical trials. Investigational sites struggle to identify the right patients and meet enrollment projections. Biopharma/CROs need to speed up the time-to-market, overcome study delays and leverage real-world and real-time data from real patients. Clinerion brings all three together on its technology platform,” says Rentsch.
“It’s an opportune time in the life sciences industry for a company like Clinerion. The company’s focus on electronic health data and innovative technologies allows it to reimagine how clinical research is conducted and how sites and patient communities around the world become engaged. A new era is coming and a data-driven approach illuminates the way to a promising future for human health.” says Rentsch.
“Clinerion is now well established. We have a truly global footprint and we are poised to expand further around the world. We can support international studies wherever they may have recruitment needs. Ian Rentsch is the right person to take the company to the next level of success,” says Ulf Claesson, current CEO and Board Director of Clinerion.
Ian Rentsch takes over from Ulf Claesson. “Ulf will continue to add his tremendous know-how to the company strategy at the board level. He has built Clinerion into a vibrant, dynamic company with a world-class team capable of moving mountains! Clinerion is in position to radically speed up clinical research to the benefit of patients around the world. Ulf has done an invaluable job in building the technological and data fundaments of Clinerion and we are fortunate to continue to have him on the Board. I’m also very happy to have in Ian a new CEO who will build the bridge between our groundbreaking offering and customers in the increasingly digitalizing healthcare environment,“ says Pierre Jaccoud, Co-Founder and Chairman of Clinerion’s Board of Directors.
Ian Rentsch’s effective start date as CEO of Clinerion will be April 1, 2018. He will attend a few upcoming events with Clinerion, including DIA Europe, the Clinical Trial Innovation Summit in Boston and he will be speaking at the MAGI EAST Clinical Research Conference.